On September 24, HENGRUI PHARMA fell 3.01% in regular trading, trading at HK$45.80/share, with turnover of approximately HK$37.63 million.

The decline was primarily driven by broad-based weakness across the pharmaceuticals sector. CSPC Pharmaceutical fell 2.12%, China Biologic Products dropped 2.46%, Hansoh Pharmaceutical declined 2.92%, and Asymchem Laboratories slid 4.64%, reflecting widespread selling pressure among industry peers.

Despite a series of positive fundamental catalysts in recent sessions — including clinical trial approvals for ten drug candidates spanning oncology, chronic kidney disease, weight management, and type 2 diabetes, as well as the acceptance of the SHR-2004 injection marketing application by the National Medical Products Administration — HENGRUI PHARMA's stock was unable to decouple from the sector downdraft. The company also continued its A-share buyback program on September 23, repurchasing 250,000 shares for approximately RMB 11.37 million, and disclosed an employee stock ownership plan covering up to 1,269 participants. BlackRock recently raised its H-share long position to 7.68%. Nonetheless, near-term price action remained dictated by sector-level risk-off sentiment rather than company-specific developments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)